Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report
| Autor: | Laila Dahmoush, Richard Piekarz, Douglas M. Kingma, Rosemary M. Altemus, Rob Robey, Susan Bakke, Victor Sandor, Maria L. Turner, Susan E. Bates, Wyndham H. Wilson |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Male
Skin Neoplasms T cell Immunology Biochemistry Peptides Cyclic Romidepsin Histones Depsipeptides Medicine T-cell lymphoma Humans Enzyme Inhibitors Aged Depsipeptide Antibiotics Antineoplastic business.industry Cutaneous T-cell lymphoma Remission Induction Lymphoma T-Cell Peripheral Acetylation Cell Biology Hematology Middle Aged medicine.disease Peripheral T-cell lymphoma Lymphoma Anti-Bacterial Agents Lymphoma T-Cell Cutaneous Histone Deacetylase Inhibitors medicine.anatomical_structure Treatment Outcome Cancer research Histone deacetylase business medicine.drug |
| Zdroj: | Blood. 98(9) |
| ISSN: | 0006-4971 |
| Popis: | Depsipeptide, FR901228, has demonstrated potent in vitro and in vivo cytotoxic activity against murine and human tumor cell lines. In the laboratory, it has been shown to be a histone deacetylase (HDAC) inhibitor. In a phase I trial of depsipeptide conducted at the National Cancer Institute, 3 patients with cutaneous T-cell lymphoma had a partial response, and 1 patient with peripheral T-cell lymphoma, unspecified, had a complete response. Sézary cells isolated from patients after treatment had increased histone acetylation. These results suggest that inhibition of HDAC is a novel and potentially effective therapy for patients with T-cell lymphoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|